Medications for the secondary prevention of ischaemic heart disease and heart failure are underutilized in dialysis patients

Internal Medicine Journal

Volumn 38, Issue 5, 2008, Pages 361-364

  Ranchord, A M ^a   Harding, S A ^a   Pidgeon, G ^a  

^a WELLINGTON HOSPITAL   (New Zealand)

Author keywords

Dialysis; Ischaemic heart disease; Left ventricular systolic dysfunction; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG CONTRAINDICATION; FEMALE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMODIALYSIS PATIENT; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTOLIC DYSFUNCTION;

EID: 42049117875     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995 47 : 186 92.
2. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998 339 : 799 805.
3. Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005 112 : 154 235.
4. Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation 2006 11 : 2363 72.
5. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA task force on practice guidelines (committee to revise the 1999 guidelines on the management of patients with acute myocardial infarction). Circulation 2004 110 : 588 636.
6. K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005 45 (Suppl. 3 S1 153.
7. Chow FY, Polkinghorne KR, Chadban SJ, Atkins RC, Kerr PG. Cardiovascular risk in dialysis patients: a comparison of risk factors and cardioprotective therapy between 1996 and 2001. Nephrology 2003 8 : 177 83.
8. Roy P, Bouchard J, Amyot R, Madore F. Prescription patterns of pharmacological agents for left ventricular systolic dysfunction among hemodialysis patients. Am J Kidney Dis 2006 48 : 645 51.
9. Martirosyan HA, Brass EP, Mehrotra R, Adler SG Cardio-Renal Responder Group and the Validation Cohort. Differential management of cardiovascular disease in ESRD by nephrologists and cardiologists. Am J Kidney Dis 2004 44 : 309 21.
10. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005 353 : 238 48.
11. Cice G, Ferrara L, D'Andrea A, D'Isa S, Di Benedetto A, Cittadini A et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am Coll Cardiol 2003 41 : 1438 44.